Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Industry News

Industry News

New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction

2026-9-28

New Progress in Early Alzheimer’s Screening: Blood Tests Are Becoming an Important Research Direction

  As the global population continues to age, early detection and early intervention for Alzheimer’s disease are receiving increasing attention from the medical community. In recent years, research on blood-based biomarkers has advanced rapidly, providing new possibilities for Alzheimer’s screening.

  A study highlighted by the U.S. National Institutes of Health in 2026 showed that researchers are exploring the use of blood biomarkers such as p-tau217 to assess Alzheimer’s-related pathological changes and potentially estimate when symptoms may begin.

  The research team analyzed repeated blood test data from 603 older adults and developed a predictive model. For some participants, the model was able to estimate the age at which Alzheimer’s symptoms might emerge, with a median prediction error of approximately three to four years.

Why Are Blood Tests Receiving So Much Attention?

  Typical pathological features of Alzheimer’s disease include the accumulation of beta-amyloid plaques and abnormal tau protein in the brain.

  Traditionally, these changes have mainly been assessed through methods such as PET brain imaging and cerebrospinal fluid testing.

  Compared with these approaches, blood testing is relatively convenient, less invasive, and potentially more affordable, making it an important area of Alzheimer’s diagnostic research.

  In August 2026, the U.S. FDA also cleared a pTau217-based blood test to assist in evaluating Alzheimer’s-related amyloid pathology in patients with signs or symptoms of cognitive impairment.

  This development further reflects the growing role of blood biomarkers in clinical assessment.

Research Is Moving Beyond “Whether” Toward “When”

  Many current Alzheimer’s blood tests are designed to help determine whether disease-related pathology is present.

  Newer research is beginning to explore another important question:

  If Alzheimer’s-related biological changes are already present, when might cognitive symptoms appear?

  Another NIH-supported study published in 2026 also found that certain circular RNAs, or circRNAs, may be associated with the future risk of developing Alzheimer’s symptoms.

  Researchers believe that these emerging biomarkers may help improve understanding of disease progression, although further validation is still required.

Why Is Early Detection Important?

  Brain changes associated with Alzheimer’s disease may begin many years before noticeable memory problems develop.

  If future screening methods can identify high-risk individuals earlier and more conveniently, doctors may be able to recommend further evaluation sooner.

  Earlier identification could also help researchers select appropriate participants for clinical trials.

  However, it is important to understand that blood biomarker testing does not mean that a person can be definitively told whether they will develop Alzheimer’s disease.

  Memory problems can also be associated with sleep disorders, depression, medication side effects, thyroid disease, vitamin deficiencies, and other neurological conditions.

  For this reason, people experiencing persistent memory decline, disorientation, language difficulties, or changes in daily functioning should seek professional medical assessment rather than relying on a single test result.

  As blood-based diagnostic technologies continue to develop, Alzheimer’s assessment may gradually become more accessible and earlier-stage focused, making this one of the most important directions in future neurodegenerative disease research.


الأخبار ذات الصلة

  • التركيز على MLD: لماذا ينبغي الكشف عن هذا الحثل الشحمي الأبيض النادر في وقت أبكر؟

    2026-10-23

  • هل يمكن تقليل خطر ألزهايمر؟ منظمة الصحة العالمية تحدد عوامل خطر الخرف القابلة للتأثير

    2026-9-28

  • علاج ألزهايمر يتقدم: من الأميلويد إلى تاو واستراتيجيات الأهداف المتعددة

    2026-9-28

  • تطورات جديدة في تحرّي ألزهايمر: اختبار الدم يتصدر اهتمام الأبحاث

    2026-9-28

  • خبر كبير! وسيط آخر من Zhongjia يحصل على إدراج FDA-DMF

    2026-7-23